Therapeutic Area

Graves' Disease

Therapeutic area intelligence for Graves' Disease with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Biohaven Therapeutics →

Assets

BHV-1300 →

Recent signals(1)

ClinicalJune 30, 2026

Biohaven's BHV-1300 Trial for Graves' Disease Underway

Biohaven Therapeutics is conducting a trial to assess the efficacy and safety of BHV-1300 in adults with Graves' disease.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Graves' Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.